The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score

Data publikacji: 19 sty 2016

Zakres stron: 269 - 272

Otrzymano: 09 gru 2014

Przyjęty: 04 cze 2015

DOI: https://doi.org/10.1515/amma-2015-0056

Słowa kluczowe

atrial fibrillation, thromboembolic events, bleeding events, oral anticoagulant treatment

© 2015 Silivastru (Cozlea) Ionela et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.